SGLT-2 (Sodium-Glucose Cotransporter 2) Inhibition Reduces Ang II (Angiotensin II)–Induced Dissecting Abdominal Aortic Aneurysm in ApoE (Apolipoprotein E) Knockout Mice

Consideration of Sex Differences in Design and Reporting of Experimental Arterial Pathology Studies—Statement From ATVB CouncilHighlights

(2018) Peggy Robinet et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Exploring novel pharmacotherapeutic applications and repurposing potential of sodium glucose CoTransporter 2 inhibitors

(2018) Tushar Madaan et al.   CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus

(2018) Seigo Sugiyama et al.   INTERNAL MEDICINE

CX3CR1/CX3CL1 Axis Mediates Platelet–Leukocyte Adhesion to Arterial Endothelium in Younger Patients with a History of Idiopathic Deep Vein Thrombosis

(2018) Elena Furio et al.   THROMBOSIS AND HAEMOSTASIS

Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress

(2018) Mahmoud El-Daly et al.   VASCULAR PHARMACOLOGY

Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms

(2018) Sarah J. Mancini et al.   Scientific Reports

Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission

(2018) Hao Zhou et al.   Redox Biology

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury

(2018) Annayya R. Aroor et al.   Cardiovascular Diabetology

Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice

(2017) Atsuo Tahara et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake

(2017) Kosuke Kaji et al.   INTERNATIONAL JOURNAL OF CANCER

The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice

(2017) Yusuke Nakatsu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Effect of a SGLT2 inhibitor on the systemic and intrarenal renin–angiotensin system in subtotally nephrectomized rats

(2017) Lei Li et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats

(2017) Sebastian Steven et al.   Redox Biology

SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice

(2017) Liang Xu et al.   EBioMedicine

Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization

(2017) Liang Xu et al.   Adipocyte

Effects of canagliflozin on weight loss in high-fat diet-induced obese mice

(2017) Wenjun Ji et al.   PLoS One

Vitamin D Receptor Activation Reduces Angiotensin-II–Induced Dissecting Abdominal Aortic Aneurysm in Apolipoprotein E–Knockout MiceHighlights

(2016) Sara Martorell et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors

(2016) Takamasa Ohki et al.   CLINICAL DRUG INVESTIGATION

Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis

(2016) Sunder Mudaliar et al.   DIABETES CARE

The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE −/− mice fed a western diet

(2016) Ji Hye Han et al.   DIABETOLOGIA

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects

(2016) Atsuo Tahara et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice

(2016) Atsuo Tahara et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

The SGLT-2 Inhibitor Dapagliflozin Has a Therapeutic Effect on Atherosclerosis in Diabetic ApoE−/−Mice

(2016) Weiling Leng et al.   MEDIATORS OF INFLAMMATION

The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice

(2016) Yasushi Honda et al.   PLoS One

Combined Sub-Optimal Doses of Rosuvastatin and Bexarotene Impair Angiotensin II-Induced Arterial Mononuclear Cell Adhesion Through Inhibition of Nox5 Signaling Pathways and Increased RXR/PPARα and RXR/PPARγ Interactions

(2015) Paula Escudero et al.   ANTIOXIDANTS & REDOX SIGNALING

Aortic Iron Overload With Oxidative Stress and Inflammation in Human and Murine Abdominal Aortic Aneurysm

(2015) H. Sawada et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Combined treatment with bexarotene and rosuvastatin reduces angiotensin-II-induced abdominal aortic aneurysm in apoE−/−mice and angiogenesis

(2015) P Escudero et al.   BRITISH JOURNAL OF PHARMACOLOGY

Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study

(2015) Rimei Nishimura et al.   Cardiovascular Diabetology

Angiotensin II and Abdominal Aortic Aneurysms: An update

(2015) Jing Liu et al.   CURRENT PHARMACEUTICAL DESIGN

SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials

(2015) Silvio E Inzucchi et al.   Diabetes & Vascular Disease Research

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus

(2015) Ian J Neeland et al.   Diabetes & Vascular Disease Research

Blood Pressure Reduction: An Added Benefit of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes: Table 1

(2015) Colleen Majewski et al.   DIABETES CARE

Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes

(2015) R. Chilton et al.   DIABETES OBESITY & METABOLISM

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Repetitive Glucose Spike and Hypoglycaemia on Atherosclerosis and Death Rate in Apo E-Deficient Mice

(2015) Kenichi Nakajima et al.   International Journal of Endocrinology

Angiotensin II Induces Region-Specific Medial Disruption during Evolution of Ascending Aortic Aneurysms

(2014) Debra L. Rateri et al.   AMERICAN JOURNAL OF PATHOLOGY

Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)

(2014) Bernard Zinman et al.   Cardiovascular Diabetology

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus

(2014) David ZI Cherney et al.   Cardiovascular Diabetology

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension

(2014) Ilkka Tikkanen et al.   DIABETES CARE

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients

(2014) Ele Ferrannini et al.   JOURNAL OF CLINICAL INVESTIGATION

The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity

(2014) Matthias Oelze et al.   PLoS One

A Systematic Review of Studies Examining Inflammation Associated Cytokines in Human Abdominal Aortic Aneurysm Samples

(2013) Alexandra L. V. Golledge et al.   DISEASE MARKERS

Potential role for anti-angiogenic therapy in abdominal aortic aneurysms

(2013) Badri Vijaynagar et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

RANTES/CCL5-induced pro-angiogenic effects depend on CCR1, CCR5 and glycosaminoglycans

(2012) N. Suffee et al.   ANGIOGENESIS

Importance of endothelial NF-κB signalling in vascular remodelling and aortic aneurysm formation

(2012) Tokuo Saito et al.   CARDIOVASCULAR RESEARCH

Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin

(2012) Jan Bolinder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Dissecting the Autocrine and Paracrine Roles of the CCR2-CCL2 Axis in Tumor Survival and Angiogenesis

(2012) Liat Izhak et al.   PLoS One

Matrix metalloproteinases in vascular physiology and disease

(2012) Suzanne A Siefert et al.   Vascular

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

(2010) Jian Chen et al.   Diabetes Therapy

Solute carrier family 2, member 9 and uric acid homeostasis

(2009) Chris Cheeseman   CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION